{"id":"W2522067962","doi":"10.1182/blood.v110.11.643.643","title":"90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Ibritumomab tiuxetan; Internal medicine; Follicular lymphoma; Tolerability; Clinical endpoint; Gastroenterology; Radioimmunotherapy; Surrogate endpoint; Rituximab; Neutropenia; Surgery; Lymphoma; Randomized controlled trial; Chemotherapy; Adverse effect; Immunology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00181791,0.0007656461,0.00150329,0.0002623383,0.0003371504,0.0005694507,0.0005291364,0.0006938646,0.002123614],"category_scores_gemma":[0.0007733352,0.0004210205,0.0009074157,0.0002799602,0.0007542795,0.0005046254,0.0002613191,0.001651367,0.0003454997],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001084826,"about_ca_system_score_gemma":0.0007666335,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001198871,"about_ca_topic_score_gemma":0.002900661,"domain_scores_codex":[0.9995458,0.0002914323,0.00002041535,0.00004286236,0.00002692594,0.00007264764],"domain_scores_gemma":[0.9994259,0.0001472029,0.0001201275,0.00005607692,0.00002452175,0.0002261817],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9268287,0.01324738,0.009039945,0.0002540466,0.0007496133,0.00008874968,0.0001370214,0.001178505,0.01050801,0.0001054478,0.001016407,0.03684609],"study_design_scores_gemma":[0.7432196,0.2272274,0.02297684,0.00003166974,0.0006285781,0.0001708542,0.00005007186,0.001234214,0.00271203,0.0001726098,0.001558073,0.00001811146],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975277,0.0008826309,0.0001769993,0.0001477527,0.00004057665,0.0005172191,0.0002555081,0.00002484802,0.000426948],"genre_scores_gemma":[0.9963708,0.0006879856,0.0005633836,0.0002217855,0.00008365824,0.000582801,0.0006795966,0.000008723476,0.000801251],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002123614,"threshold_uncertainty_score":0.00961417,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01568203947190317,"score_gpt":0.2934166943824472,"score_spread":0.2777346549105441,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}